Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases
TCZ shows rapid and maintained effectiveness in all GCA phenotypes in clinical remission and EULAR complete remission. By contrast, absence of inflammation as shown using imaging techniques was much lower in ecGCA and mixGCA.
Authors
- Iván Ferraz‐Amaro (ORCID: https://orcid.org/0000-0003-0197-5267)
- Santos Castañeda (ORCID: https://orcid.org/0000-0002-7748-853X)
- O. Maíz
- Vicente Aldasoro
- Eugenio de Miguel (ORCID: https://orcid.org/0000-0001-5146-1964)
- F. López-Gutiérrez
- J. Loricera (ORCID: https://orcid.org/0000-0003-4754-0277)
- Susana Romero-Yuste
- Ricardo Blanco (ORCID: https://orcid.org/0000-0003-2344-2285)
- R. Melero
Institutions
- Hospital Universitario de Canarias (ES)
- Hospital Universitario La Paz (ES)
- University Hospital Complex Of Vigo (ES)
- Complejo Hospitalario de Navarra (ES)
- Biogipuzkoa Health Research Institute (ES)
- Instituto de Investigación Marqués de Valdecilla (ES)
- Hospital Universitario de La Princesa (ES)
- Donostiako Unibertsitate Ospitalea (ES)
- Complexo Hospitalario Universitario A Coruña (ES)
- Roche (Spain) (ES)
- Complejo Hospitalario de Pontevedra (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1093/rheumatology/keae666
- Citations
- 6
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 2.51
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Celgene
- Instituto de Salud Carlos III
- European Regional Development Fund
- UCB Pharma